LXEO
Lexeo TherapeuticsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
LXEO Profile
Lexeo Therapeutics, Inc.
A clinical-stage genetic medicine company treating cardiovascular disease and Alzheimer's disease
345 Park Avenue South, Floor 6, New York, New York 10010
--
Lexeo Therapeutics, Inc., formed on February 17, 2017, is a limited liability company organized under the laws of the State of Delaware under the legal name Lexeo Therapeutics, LLC. The Company converted the LLC to Lexeo Therapeutics, Inc., a Delaware-based company on November 20, 2020. The company is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying groundbreaking science to fundamentally change the way diseases are treated. The company's most advanced cardiovascular product candidate, LX 2006, is currently in an ongoing Phase 1/2 clinical trial for the treatment of patients with Friedreich's ataxia (FA) cardiomyopathy. The company's second advanced cardiovascular product candidate, LX2020, for the treatment of arrhythmogenic cardiomyopathy caused by mutations in the PKP 2 gene, referred to as PKP 2-ACM, received IND approval from the U.S. Food and Drug Administration (FDA) in July 2023.
